Asha Therapeutics CSO, Dr. Bradlee Heckmann speaking at AD/PD 2023

Asha Therapeutics' scientific co-founder and CSO, Dr. Bradlee Heckmann will be presenting at the international AD/PD 2023 meeting in Sweden

Asha Therapeutics CSO, Dr. Bradlee Heckmann will be sharing new data on Asha's efforts to advance lead assets including ASHA-091 towards clinic. The AD/PD 2023 meeting is the pre-eminent conference focusing on Alzheimer's Disease and Parkinson's Disease pathogenesis and therapeutic development.